{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T18:02:48Z","timestamp":1704564168999},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11307-015-0840-x","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T20:58:56Z","timestamp":1426107536000},"page":"697-703","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model"],"prefix":"10.1007","volume":"17","author":[{"given":"Z\u00e9na","family":"Wimana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gebhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Vanderlinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Morandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Doumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Van Simaeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"840_CR1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","volume":"13","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Moasser MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13:527\u2013534","journal-title":"Trends Mol Med"},{"key":"840_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/1477-3163.90442","volume":"10","author":"TA Bailey","year":"2011","unstructured":"Bailey TA, Luan H, Clubb RJ et al (2011) Mechanisms of trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 10:28","journal-title":"J Carcinog"},{"key":"840_CR3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","volume":"312","author":"AL Schechter","year":"1984","unstructured":"Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513\u2013516","journal-title":"Nature"},{"key":"840_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"840_CR5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00280-009-1208-1","volume":"65","author":"A Davoli","year":"2010","unstructured":"Davoli A, Hocevar BA, Brown TL (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 65:611\u2013623","journal-title":"Cancer Chemother Pharmacol"},{"key":"840_CR6","first-page":"743193","volume":"2012","author":"Z Mitri","year":"2012","unstructured":"Mitri Z, Constantine T, O\u2019Regan R (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193","journal-title":"Chemother Res Pract"},{"key":"840_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2010.01711.x","volume":"102","author":"T Mukohara","year":"2011","unstructured":"Mukohara T (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 102:1\u20138","journal-title":"Cancer Sci"},{"key":"840_CR8","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","volume":"15","author":"PR Pohlmann","year":"2009","unstructured":"Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15:7479\u20137491","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"840_CR9","first-page":"224","volume":"1815","author":"P Mukhopadhyay","year":"2011","unstructured":"Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224\u2013240","journal-title":"Biochim Biophys Acta"},{"key":"840_CR10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1011327708973","volume":"6","author":"KL Carraway","year":"2001","unstructured":"Carraway KL, Price-Schiavi SA, Komatsu M et al (2001) Muc4\/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 6:323\u2013337","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"840_CR11","doi-asserted-by":"crossref","first-page":"352182","DOI":"10.4061\/2011\/352182","volume":"2011","author":"GL Fiszman","year":"2011","unstructured":"Fiszman GL, Jasnis MA (2011) Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer 2011:352182","journal-title":"Int J Breast Cancer"},{"key":"840_CR12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.10410","volume":"99","author":"SA Price-Schiavi","year":"2002","unstructured":"Price-Schiavi SA, Jepson S, Li P et al (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer J Int Cancer 99:783\u2013791","journal-title":"Int J Cancer J Int Cancer"},{"key":"840_CR13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","volume":"65","author":"P Nagy","year":"2005","unstructured":"Nagy P, Friedl\u00e4nder E, Tanner M et al (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473\u2013482","journal-title":"Cancer Res"},{"key":"840_CR14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586\u2013592","journal-title":"Clin Pharmacol Ther"},{"key":"840_CR15","doi-asserted-by":"crossref","unstructured":"OudeMunnink TH, Korte MA, Nagengast WB et al (2010) (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 46:678\u2013684","DOI":"10.1016\/j.ejca.2009.12.009"},{"key":"840_CR16","first-page":"974","volume":"50","author":"ECF Dijkers","year":"2009","unstructured":"Dijkers ECF, Kosterink JGW, Rademaker AP et al (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging. J Nucl Med Off Publ Soc Nucl Med 50:974\u2013981","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"840_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2006.09.014","volume":"172","author":"K Rennstam","year":"2007","unstructured":"Rennstam K, J\u00f6nsson G, Tanner M et al (2007) Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet 172:95\u2013106","journal-title":"Cancer Genet Cytogenet"},{"key":"840_CR18","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/sj.onc.1208756","volume":"24","author":"M Andrianifahanana","year":"2005","unstructured":"Andrianifahanana M, Agrawal A, Singh AP et al (2005) Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene 24:6143\u20136154","journal-title":"Oncogene"},{"key":"840_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-11-24","volume":"11","author":"S Kunigal","year":"2012","unstructured":"Kunigal S, Ponnusamy MP, Momi N et al (2012) Nicotine, IFN-\u03b3 and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades. Mol Cancer 11:24","journal-title":"Mol Cancer"},{"key":"840_CR20","doi-asserted-by":"crossref","first-page":"33929","DOI":"10.1074\/jbc.M005115200","volume":"275","author":"A Choudhury","year":"2000","unstructured":"Choudhury A, Singh RK, Moniaux N et al (2000) Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway. J Biol Chem 275:33929\u201333936","journal-title":"J Biol Chem"},{"key":"840_CR21","doi-asserted-by":"crossref","first-page":"e12333","DOI":"10.1371\/journal.pone.0012333","volume":"5","author":"J Clark","year":"2010","unstructured":"Clark J, Clore EL, Zheng K et al (2010) Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 5:e12333","journal-title":"PLoS One"},{"key":"840_CR22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2005.10.041","volume":"47","author":"AJ Marian","year":"2006","unstructured":"Marian AJ, Senthil V, Chen SN, Lombardi R (2006) Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 47:827\u2013834","journal-title":"J Am Coll Cardiol"},{"key":"840_CR23","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.patcog.2008.08.011","volume":"42","author":"I Naqa El","year":"2009","unstructured":"El Naqa I, Grigsby P, Apte A et al (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn 42:1162\u20131171","journal-title":"Pattern Recogn"},{"key":"840_CR24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-011-1845-6","volume":"38","author":"FHP Velden Van","year":"2011","unstructured":"Van Velden FHP, Cheebsumon P, Yaqub M et al (2011) Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 38:1636\u20131647","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"840_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1054-3589(08)60985-0","volume":"38","author":"IA Cotgreave","year":"1997","unstructured":"Cotgreave IA (1997) N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol San Diego Calif 38:205\u2013227","journal-title":"Adv Pharmacol San Diego Calif"},{"key":"840_CR26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00345-001-0234-3","volume":"20","author":"BP Schrier","year":"2002","unstructured":"Schrier BP, Lichtendonk WJ, Witjes JA (2002) The effect of N-acetyl-l-cysteine on the viscosity of ileal neobladder mucus. World J Urol 20:64\u201367","journal-title":"World J Urol"},{"key":"840_CR27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.bjc.6602110","volume":"91","author":"C Lorenzo De","year":"2004","unstructured":"De Lorenzo C, Tedesco A, Terrazzano G et al (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91:1200\u20131204","journal-title":"Br J Cancer"},{"key":"840_CR28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/carcin\/bgi146","volume":"26","author":"CD Lorenzo","year":"2005","unstructured":"Lorenzo CD, Cozzolino R, Carpentieri A et al (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26:1890\u20131895","journal-title":"Carcinogenesis"},{"key":"840_CR29","first-page":"1357","volume":"48","author":"DL Costantini","year":"2007","unstructured":"Costantini DL, Chan C, Cai Z et al (2007) (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2\/neu-amplified breast cancer. J Nucl Med Off Publ Soc Nucl Med 48:1357\u20131368","journal-title":"J Nucl Med Off Publ Soc Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-015-0840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-015-0840-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-015-0840-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T18:09:04Z","timestamp":1691518144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-015-0840-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s11307-015-0840-x","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}